Clinical Trials
7 trialsNCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT02149108 2017-07-21
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Boehringer Ingelheim
Phase 3 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01594125 2016-02-12
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT00904839 2015-02-04
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed